Comparison of Guaiac-Based and Quantitative Immunochemical Fecal Occult Blood Testing in a Population at Average Risk Undergoing Colorectal Cancer Screening
- 1 September 2010
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in American Journal Of Gastroenterology
- Vol. 105 (9), 2017-2025
- https://doi.org/10.1038/ajg.2010.179
Abstract
Although some studies have shown that the quantitative, immunochemical fecal occult blood test (FOBT) (qFIT) has better performance characteristics than the standard guaiac-based FOBT (GT) for identifying advanced colorectal neoplasia (ACRN), there is limited information on test performance of these tests in average-risk populations. Seven hundred seventy consecutive average-risk patients from four centers who were undergoing screening colonoscopy also provided stool samples. Stool specimens from three consecutive bowel movements were applied to a hemoccult II test card (Beckman Coulter, Fullerton, CA) and OC-SENSA MICRO (Eiken Chemical, Tokyo, Japan) sampling probes at the same time. We measured the diagnostic value of the qFIT for detecting an ACRN by using three criteria: sensitivity, specificity, and likelihood ratios. A receiver operating characteristic curve for determining the qFIT cutoff values and the number of tests that best discriminated between ACRNs and other findings were determined. Seventy-eight ACRNs were identified during colonoscopy. At all hemoglobin thresholds, the sensitivity of the qFIT was higher than that of the GT for cancer or ACRN. The sensitivity and specificity of the GT for detecting advanced adenomas, cancer, and ACRNs were 13.6%/92.4%, 30.8%/92.4%, and 16.7%/92.9%, respectively. Using the 100 ng/ml cut point and three-sample qFIT results, the sensitivity and specificity of the qFIT for detecting advanced adenomas, cancer, and ACRNs were 33.9%/90.6%, 84.6%/89.8%, and 43.7%/91.9%, respectively. The area under the curve for cancer indicated that using either 2 or 3 tests provided the best discrimination for cancer. The qFIT provides a higher sensitivity for detecting ACRN and cancer than the GT, and has an acceptable specificity that significantly reduces the need for colonoscopic evaluation in the screened population.This publication has 35 references indexed in Scilit:
- Quantitative colonoscopic evaluation of relative efficiencies of an immunochemical faecal occult blood test and a sensitive guaiac test for detecting significant colorectal neoplasmsAlimentary Pharmacology & Therapeutics, 2009
- Global Cancer Statistics, 2002CA: A Cancer Journal for Clinicians, 2005
- Fecal DNA versus Fecal Occult Blood for Colorectal-Cancer Screening in an Average-Risk PopulationNew England Journal of Medicine, 2004
- Evaluation of an automated immunochemical fecal occult blood test for colorectal neoplasia detection in a Chinese populationCancer, 2003
- Evaluation of the optimum cut-off point in immunochemical occult blood testing in screening for colorectal cancerEuropean Journal Of Cancer, 2001
- The Effect of Fecal Occult-Blood Screening on the Incidence of Colorectal CancerNew England Journal of Medicine, 2000
- Review article: faecal occult blood testing for colorectal cancerAlimentary Pharmacology & Therapeutics, 1998
- Randomised study of screening for colorectal cancer with faecal-occult-blood testThe Lancet, 1996
- Randomised controlled trial of faecal-occult-blood screening for colorectal cancerThe Lancet, 1996
- Reducing Mortality from Colorectal Cancer by Screening for Fecal Occult BloodNew England Journal of Medicine, 1993